Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and ...

One disease that arises from disruptions in the cell cycle is cancer. After a series of events, a normal cell begins to divide uncontrollably and becomes a tumour cell. Breast tumours are a complex ...

New genomic research suggests our species descended from a deep fusion between two ancient lineages — one of them a ...

ABSTRACT: Polymorphisms in certain human genes may contribute to the development of gynecological cancers. While infection with human papillomavirus (HPV) is considered the main cause, studies suggest ...

Detailed price information for Solid Biosciences Inc (SLDB-Q) from The Globe and Mail including charting and trades.

In this review, Brian Tait, Chief Scientific Officer, Haplomic Technologies Pty Ltd, examines critical aspects of cancer genetic research, emphasising genes that may benefit from single-chromosome ...

Donor-Specific B Cells in Transplantation. The major goal of this project is to determine the properties of donor-specific B cells in recipients that maintain stable graft function and in those that ...

The etiopathogenesis of ankylosing spondylitis (AS) is not fully understood. However, there is strong evidence indicating that genetic factors play a pivotal role in disease susceptibility, and that ...

Version of Record: This is the final version of the article. In this study, the authors characterized population genetic variation in the MHC locus across primates and looked for signals of long-term ...

Solid Biosciences is planning a phase 1b clinical trial of SGT-501 to treat the catecholaminergic polymorphic ventricular tachycardia heart condition. On July 23, 2025, the FDA granted fast track ...

Solid Biosciences announces Phase 1b trial for SGT-501, a gene therapy for catecholaminergic polymorphic ventricular tachycardia, with FDA designations. Solid Biosciences Inc. has announced the ...

CHARLESTOWN, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular ...